Cargando…
Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019
BACKGROUND: Financial relationships between healthcare professionals and pharmaceutical companies have historically caused conflicts of interest and unduly influenced patient care. However, little was known about such relationship and its effect in clinical practice among specialists in respiratory...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811425/ https://www.ncbi.nlm.nih.gov/pubmed/36353778 http://dx.doi.org/10.1159/000526576 |
_version_ | 1784863529711435776 |
---|---|
author | Murayama, Anju Hoshi, Momoko Saito, Hiroaki Kamamoto, Sae Tanaka, Manato Kawashima, Moe Mamada, Hanano Kusumi, Eiji Sapkota, Binaya Shrestha, Sunil Shrestha, Rajeev Bhandari, Divya Sawano, Toyoaki Yamashita, Erika Tanimoto, Tetsuya Ozaki, Akihiko |
author_facet | Murayama, Anju Hoshi, Momoko Saito, Hiroaki Kamamoto, Sae Tanaka, Manato Kawashima, Moe Mamada, Hanano Kusumi, Eiji Sapkota, Binaya Shrestha, Sunil Shrestha, Rajeev Bhandari, Divya Sawano, Toyoaki Yamashita, Erika Tanimoto, Tetsuya Ozaki, Akihiko |
author_sort | Murayama, Anju |
collection | PubMed |
description | BACKGROUND: Financial relationships between healthcare professionals and pharmaceutical companies have historically caused conflicts of interest and unduly influenced patient care. However, little was known about such relationship and its effect in clinical practice among specialists in respiratory medicine. METHODS: Based on the retrospective analysis of payment data made available by all 92 pharmaceutical companies in Japan, this study evaluated the magnitude and trend of financial relationships between all board-certified Japanese respiratory specialists and pharmaceutical companies between 2016 and 2019. Magnitude and prevalence of payments for specialists were analyzed descriptively. The payment trends were assessed using the generalized estimating equations for the payment per specialist and the number of specialists with payments. RESULTS: Among all 7,114 respiratory specialists certified as of August 2021, 4,413 (62.0%) received a total of USD 53,547,391 and 74,195 counts from 72 (78.3%) pharmaceutical companies between 2016 and 2019. The median (interquartile range) 4-year combined payment values per specialist were USD 2,210 (USD 715–8,178). At maximum, one specialist received USD 495,332 personal payments over the 4 years. Both payments per specialist and number of specialists with payments significantly increased during the 4-year period, with 7.8% (95% CI: 5.5–9.8; p < 0.001) in payments and 1.5% (95% CI: 0.61–2.4; p = 0.001) in number of specialists with payments, respectively. CONCLUSION: The majority of respiratory specialists had increasingly received more personal payments from pharmaceutical companies for the reimbursement of lecturing, consulting, and writing between 2016 and 2019. These increasing financial relationships with pharmaceutical companies might cause conflicts of interest among respiratory physicians. |
format | Online Article Text |
id | pubmed-9811425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-98114252023-01-05 Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019 Murayama, Anju Hoshi, Momoko Saito, Hiroaki Kamamoto, Sae Tanaka, Manato Kawashima, Moe Mamada, Hanano Kusumi, Eiji Sapkota, Binaya Shrestha, Sunil Shrestha, Rajeev Bhandari, Divya Sawano, Toyoaki Yamashita, Erika Tanimoto, Tetsuya Ozaki, Akihiko Respiration Clinical Investigations BACKGROUND: Financial relationships between healthcare professionals and pharmaceutical companies have historically caused conflicts of interest and unduly influenced patient care. However, little was known about such relationship and its effect in clinical practice among specialists in respiratory medicine. METHODS: Based on the retrospective analysis of payment data made available by all 92 pharmaceutical companies in Japan, this study evaluated the magnitude and trend of financial relationships between all board-certified Japanese respiratory specialists and pharmaceutical companies between 2016 and 2019. Magnitude and prevalence of payments for specialists were analyzed descriptively. The payment trends were assessed using the generalized estimating equations for the payment per specialist and the number of specialists with payments. RESULTS: Among all 7,114 respiratory specialists certified as of August 2021, 4,413 (62.0%) received a total of USD 53,547,391 and 74,195 counts from 72 (78.3%) pharmaceutical companies between 2016 and 2019. The median (interquartile range) 4-year combined payment values per specialist were USD 2,210 (USD 715–8,178). At maximum, one specialist received USD 495,332 personal payments over the 4 years. Both payments per specialist and number of specialists with payments significantly increased during the 4-year period, with 7.8% (95% CI: 5.5–9.8; p < 0.001) in payments and 1.5% (95% CI: 0.61–2.4; p = 0.001) in number of specialists with payments, respectively. CONCLUSION: The majority of respiratory specialists had increasingly received more personal payments from pharmaceutical companies for the reimbursement of lecturing, consulting, and writing between 2016 and 2019. These increasing financial relationships with pharmaceutical companies might cause conflicts of interest among respiratory physicians. S. Karger AG 2022-12 2022-11-09 /pmc/articles/PMC9811425/ /pubmed/36353778 http://dx.doi.org/10.1159/000526576 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Clinical Investigations Murayama, Anju Hoshi, Momoko Saito, Hiroaki Kamamoto, Sae Tanaka, Manato Kawashima, Moe Mamada, Hanano Kusumi, Eiji Sapkota, Binaya Shrestha, Sunil Shrestha, Rajeev Bhandari, Divya Sawano, Toyoaki Yamashita, Erika Tanimoto, Tetsuya Ozaki, Akihiko Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019 |
title | Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019 |
title_full | Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019 |
title_fullStr | Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019 |
title_full_unstemmed | Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019 |
title_short | Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019 |
title_sort | nature and trends in personal payments made to the respiratory physicians by pharmaceutical companies in japan between 2016 and 2019 |
topic | Clinical Investigations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811425/ https://www.ncbi.nlm.nih.gov/pubmed/36353778 http://dx.doi.org/10.1159/000526576 |
work_keys_str_mv | AT murayamaanju natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT hoshimomoko natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT saitohiroaki natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT kamamotosae natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT tanakamanato natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT kawashimamoe natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT mamadahanano natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT kusumieiji natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT sapkotabinaya natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT shresthasunil natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT shrestharajeev natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT bhandaridivya natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT sawanotoyoaki natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT yamashitaerika natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT tanimototetsuya natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 AT ozakiakihiko natureandtrendsinpersonalpaymentsmadetotherespiratoryphysiciansbypharmaceuticalcompaniesinjapanbetween2016and2019 |